Sage plans to lay off almost every employee after reaching deal with Supernus
After announcing a buyer earlier this month, Sage Therapeutics now plans to lay off virtually all of its employees. The company disclosed the workforce reduction in a WARN notice in Massachusetts ...
View ArticlePfizer ends Phase 2 trial for final Trillium CD47 drug
Pfizer has terminated a trial testing the second of two CD47 programs it received from the 2021 buyout of Trillium Therapeutics, marking a setback for the $2.3 billion acquisition. The company axed a...
View ArticleSupreme Court passes on Oklahoma’s drug middlemen spat
The US Supreme Court on Monday declined to take up a case that could have clarified the extent to which states can regulate pharmacy benefit managers without preempting federal law. The justices denied...
View ArticleProtagonist unveils 'triple-G' obesity pill, but human trials are nearly a...
Protagonist Therapeutics is a late entrant into the obesity space, but it cannot be accused of following the crowd. The California-based biotech unveiled its only obesity candidate, which is still in ...
View ArticleExclusive: Bob Langer-founded Syntis Bio gets $33M Series A for obesity, rare...
A Boston biotech working on a different approach to oral obesity drugs collected a $33 million Series A, with plans to enter the clinic later this year, the company exclusively told Endpoints News....
View ArticleBeckley touts positive mid-stage psychedelic data, advancing atai merger
Beckley Psytech said its intranasal treatment bested a small-dose comparator in a Phase 2b trial of patients with treatment-resistant depression, notching another win for the burgeoning psychedelic...
View ArticleUnnatural Products taps argenx's help for ringed molecules, expands internal...
Unnatural Products has signed on argenx as its latest partner to take forward its approach to ringed molecules. Argenx will deliver unspecified upfront money in the double-digit millions to the Santa...
View ArticleSama Fertility raises $3.8M to make IVF more accessible
Sama Fertility has raised $3.8 million to help people undergo IVF, mostly at home, Endpoints News learned exclusively. With seed funding, Sama is launching a program called SimpleIVF, which requires...
View ArticleKevin Tang's Concentra snags another buyout, this time for IGM Biosciences
Kevin Tang is on a hot streak. Concentra Biosciences, the shell company from his hedge fund Tang Capital, has secured its fourth buyout of a struggling biotech so far in 2025. This time, Concentra is ...
View ArticleAdvocates urge J&J to ‘put everything on the table’ for gene therapy despite...
For Lewis Winton, the world looks different from one eye. In the first few months after getting a gene therapy in his right eye, Winton kept covering his other eye with his hand. Winton, a ...
View ArticleBroad Institute conducts layoffs as it preps for cuts in federal funding;...
Plus, news about Bayer, Tempus AI, Apellis, Sobi, Nektar Therapeutics, Cybin, atai Life Sciences, HanchorBio, Henlius, Portal Biotech, Roche, AvenCell Therapeutics, Adagene and BerGenBio: Broad...
View ArticleThe biggest health tech stories of 2025 — so far
We’re officially halfway through 2025. Rather than wait for the end of the year to reflect, the Health Tech team looked at our notebooks to see what transpired in the first six months of the ...
View ArticleAN Venture Partners lines up $200M freshman fund to champion Japanese innovation
At a time when few biotech venture capital firms are coming out of the gates, a Japan-focused investor is doing so and has closed a $200 million fund. AN Venture Partners, or ANV, initially ...
View ArticlePBM reforms fail to make Senate version of Trump's megabill
Efforts to rein in pharmacy benefit managers, for which drugmakers have been building bipartisan support over the years, were left out of the Senate-passed version of President Donald Trump’s megabill....
View ArticleFederal judge orders block on parts of HHS reorganization plan after states sue
A Rhode Island judge on Tuesday issued a preliminary injunction against parts of the Trump administration’s plan to restructure the federal health agencies. “The States have shown a likelihood of...
View ArticleShionogi, BioVersys team up on ansamycin antibiotics in deal worth up to $614M
BioVersys is entering a pact with Shionogi to advance the Swiss biotech’s antibiotic program targeting non-tuberculous mycobacteria, with over half a billion dollars in biobucks on the line. Shionogi...
View ArticleSoriot mulls moving AstraZeneca stock listing to the US — report
AstraZeneca CEO Pascal Soriot is reportedly considering moving the company’s stock listing from the UK to the US. He also privately mooted the idea of changing the pharma company’s domicile, according...
View ArticleOrganon stops work on drug once viewed as ‘game-changing’; NextPoint culls an...
Plus, news about ArriVent BioPharma, Everest Medicines, Ribocure, Paradigm Biopharmaceuticals, Verrica and Torii: Organon discontinues experimental therapy for endometriosis-related pain: The Merck...
View ArticleUS investors divided on China's biotech rise
China’s ascent in drug development has kicked off debate among American investors over how to respond. Chinese companies are now competitive in some of the hottest areas of drug research, including...
View ArticleAbbVie cans oral ulcerative colitis drug from Landos buyout
AbbVie terminated work on the main drug from last year's $137 million buyout of Landos Biopharma. It's an abrupt end for ABBV-113, formerly known as NX-13, in ulcerative ...
View Article
